ClinicalTrials.gg
Active, not recruitingNCT07949084FIT-PETUpdated Nov 19, 2026

The FIT-PET Study: Is Increased Cerebral Blood Flow a Mediator of the Beneficial Effects of HIIT-training on Cognitive Performance in Elderly Patients With Type 2 Diabetes?

An interventional study of HIIT-training in Microvascular Disease, Microvascular Complications and Dementia, sponsored by University Hospital Bispebjerg and Frederiksberg. Active, not recruiting at 1 site in Denmark. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University Hospital Bispebjerg and Frederiksberg · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Jul 2025, registered Nov 2026).
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies in Dementia with a site in Denmark — 6 open to participants now, 12 under way, 1 of them phase 3. Dementia · Denmark.

Enrollment
16th of 21
44 · median 339
Started
2025
with 5 others
No phase
10 of 30
2 open now
Primary completion
2027-12
later than 7 of 11 live
Registered
30th of 30
by date
Lead sponsor
3 of 30
University Hospital Bispebjerg and Frederiksberg

Among the 30 studies in Dementia with a site in Denmark, this one is the 16th largest by enrollment of the 21 interventional ones that give a count, is one of 6 that started in 2025, is one of 10 with no phase, reaches primary completion later than 7 of the 11 other live ones, and was the 30th registered.

Dementia

2,376 studies on the registry are indexed under Dementia; 573 are open to participants now.

Browse Dementia studies →

Open to participants now

6 of the 30 studies in Dementia with a site in Denmark are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 382 Dementia studies recruiting now, 243 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 163 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Dementia with a site in Denmark, or all of them as a file.
02

Study summary

In the aging population, ischemic heart disease, stroke and dementia are increasingly prevalent. Diagnosis and treatment of the former two i.e., large-vessel coronary heart disease and endovascular thrombectomy of the brain in relation to stroke have improved significantly. Yet, the majority of elderly patients with ischemic heart disease do not have large-vessel heart disease and it seems that small vessel disease (SVD) may explain a large fraction of these cases as well as the cardiovascular morbidity in the elderly. Hence, the current development in diagnostics and treatments of ischemic heart disease does not address the most common subtype of ischemic disease seen in elderly patients.It has been suggested that SVD is part of a multisystem disorder and several systematic reviews have addressed the hypothesis of a potential link between small vessel disease of the heart, brain, and kidneys. Cerebral SVD is prevalent in the aging population causing cognitive impairment, dementia, and an increased risk of stroke, and cerebral hypoperfusion is an acknowledged cause of vascular dementia and a possible cause of Alzheimer's disease. Further, cognitive impairment within multiple cognitive domains is highly prevalent in heart failure and is associated to an increased risk of dementia. The link between heart failure and dementia may be due to multisystem SVD, although a direct link between the two is possible.Among other known risk factors such as age, hypertension, and female sex, diabetes is a major cause of SVD and is linked to coronary heart disease as well as cognitive impairment. The diagnosis of cerebral SVD relies on MRI detecting infarctions, haemorrhages, microbleeds and ischemic white matter changes, i.e. Fazekas score. In contrast, perfusion PET is used to image myocardial perfusion in patients with coronary SVD; and coronary SVD is recognized as a part of the pathophysiology in angina, coronary artery disease, and heart failure. Perfusion PET before and after adenosine-induced vasodilation allows for measuring, the myocardial flow reserve (MFR), i.e. perfusion capacity, which in the absence of regional perfusion defects, is a measure of coronary SVD. Prof. Eva Prescott have recently shown that reduced MFR obtained by 82Rb PET is a strong predictor of future microvascular events and all-cause mortality.Exercise is well known to improve cognitive health but professor Carl-Johan Boraxbekk has shown that the effect on cognitive performance may be dependent on the initial cerebrovascular status, as patients with moderate to severe white matter changes did not improve after a 6 months physical activation intervention in contrast to patients with mild changes. Yet, it is possible to improve brain function in diabetic patients through either dietary or exercise interventions. Systemic SVD is measured as cerebral SVD (reduced brain perfusion during acetazolamide-induced vasodilation) and coronary SVD (reduced heart perfusion during adenosine-induced vasodilation). The researchers anticipate that patients with type 2 dabetes have reduced perfusion capacity of the brain and heart correlating to reduced cognition and cardiorespiratory fitness (VO2-max). Therefore we wish to see if we can improve both CBF and cognitive performance by improving VO2-max through a 16 week HIIT-training intervention.

Read the detailed description

We aim to include 40-48 patients with diabetes. They will then undergo baseline-testing consisting of CPET, 15O-PET measures of CBF and MBF, brain MRI, blood sampling (basic health check), cognitive testing (SCIP-D + CANTAB) and echocardiography to rule out significant LV failure.

After that they will be randomixed to either 4 months of twice weekly supervised HIIT-training or a control group that does not train additionally.

After the intervention, the patients will undergo retesting with the same tests from baseline except for brain MR.

03

Conditions studied

  • Microvascular Disease
  • Microvascular Complications
  • Dementia
  • Diabetes Type 2
  • Cerebral Hypoperfusion

Keywords

  • microvascular disease
  • microvascular complications of the heart
  • microvascular complications of the brain
  • diabetes type 2
  • dementia
  • microvascular disease patophysiology
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diabetes type II diagnose with one of the following:

  • Duration over 5 years
  • Moderate microalbuminuria
  • Non-proliferative diabetic retinopathy

    • Speaks and understands Danish (required for reliable cognitive testing)
    • Able to provide informed and written consent

Exclusion criteria

Exclusion Criteria:

  • Moderate to high intensity training > 1 times/week.

    • Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF ( \< 45%), asthma.
    • Previous stroke or significant neurological disease including cognitive dysfunction.
    • Ongoing depression.
    • Hypothyroidism
    • Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    HIIT-training

    4 months of twice weekly supervised HIIT-training on bikes

    Other: HIIT-training

  • No intervention
    Control

    Control group who lives on as usual

Interventions

  • OtherHIIT-training

    4 months of twice weekly supervised HIIT-training on indoor bikes.

06

What researchers measure

Primary outcomes

  1. [15O]H2O PET assessment of the blood perfusion to the brain

    Cerebral Blood Perfusion

    Time frame: From baseline testing to end of study, 6 months

  2. [15O]H2O PET assessment of the blood perfusion of the heart

    Myocardial Blood Perfusion

    Time frame: From baseline testing to end of study, 6 months

Secondary outcomes

  1. Cognitive performance (CANTAB)

    Testing of a broad range of cognitive functions. The test is tablet based and one of the most used investigator-independent cognitive tests available. The test takes around 45 minutes to perform.

    Time frame: From baseline testing to end of study, 6 months

  2. Cognitive Performance (SCIP-D)

    Assessed via SCIP-D in order to evaluate a broad range of cognitive areas in around 15-20 minutes. Both groups will undergo both tests. The primary investigator will receive learning in how to carry out the SCIP-D correctly. SCIP-D is a more clinically relevant test that can be used in a clinical setting to identify patients with cognitive dysfunction.

    Time frame: From baseline testing to end of study, 6 months

  3. Cardiorespiratory fitness (VO2-max)

    Will be assessed as the maximal or peak oxygen consumption (VO2-max or VO2-peak) during a cardiopulmonal exercise test (CPET).

    Time frame: From baseline testing to end of study, 6 months

07

Study locations

1 site
  • University Hospital Bispebjerg og Frederiksberg Hospital
    Copenhagen, 2400, Denmark
08

References and documents

Individual participant data

Plan to share: No — Have not gotten the necessary clearence

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.

Of 861 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 29 months is above that.

Counting every sponsor, half of 907 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartActual
Jul 1, 2025
Primary completionEst.
Dec 2, 2027
CompletionEst.
Dec 2, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949084
Lead sponsor
University Hospital Bispebjerg and Frederiksberg
Responsible party
Thomas Ehlig Hjermind Justesen (M.D., University Hospital Bispebjerg and Frederiksberg) — Principal investigator
First posted
Nov 19, 2026
Start date
Jul 1, 2025
Primary completion
Dec 2, 2027 (estimated)
Completion
Dec 2, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Thomas EHJ Justesen, Medical Doctor
principal investigator · Universitetshospital Bispebjerg og Frederiksberg Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion